Estimate your prostate cancer risk
Enter your screening details below. This tool gives an educational estimate only and does not diagnose cancer.
What this risk prostate cancer calculator does
This calculator combines common prostate cancer screening variables into a single estimated risk score. It is designed for men who are discussing screening results and wondering whether further evaluation might be reasonable. It uses practical factors that clinicians often consider: age, PSA value, DRE findings, family history, ancestry risk, and prior biopsy history.
The output is presented as an estimated probability category (low, mild, moderate, or high concern) and includes a suggested next step for conversation with a healthcare professional. It is intentionally conservative and educational, not diagnostic.
How the score is calculated
1) Baseline + age contribution
Prostate cancer risk generally increases with age. The model assigns a larger contribution at older ages, especially after age 60.
2) PSA contribution
PSA (prostate-specific antigen) is one of the strongest screening indicators. As PSA rises, estimated risk rises nonlinearly. A very high PSA substantially shifts the score upward.
3) Clinical and family risk modifiers
- Abnormal DRE raises risk because a suspicious exam may indicate underlying pathology.
- First-degree family history (father or brother with prostate cancer) increases risk.
- Black/African ancestry is included because population-level studies show higher average incidence and worse outcomes.
- Prior negative biopsy lowers current estimated risk slightly, though it does not eliminate risk.
4) Optional free PSA%
Lower free PSA percentages can indicate higher probability of cancer in selected PSA ranges, so this optional field can fine-tune the estimate.
How to interpret your result
The estimate is grouped into practical categories:
- Low concern (<10%): continue routine follow-up based on your clinician's advice.
- Mild concern (10-24%): discuss repeat PSA timing and trend monitoring.
- Moderate concern (25-49%): consider referral to urology and additional testing.
- High concern (50%+): prompt specialist evaluation is typically appropriate.
You will also see an estimated high-grade risk marker. This is a rough educational indicator of whether a more aggressive cancer pattern could be present, based on the same clinical inputs.
What to do after using this tool
Bring your numbers to your appointment
Print or screenshot your age, PSA, and calculator result. A clinician can compare this with lab trends, prostate size, MRI findings, and medication history to make a better decision than any calculator alone.
Review PSA trend, not just one value
A single PSA can be affected by prostatitis, ejaculation timing, urinary retention, recent cycling, or recent procedures. Trend over time is often more informative than one isolated result.
Ask about next-step options
- Repeat PSA after a clinically appropriate interval
- Percent free PSA or other biomarker testing
- Multiparametric prostate MRI
- Targeted or systematic prostate biopsy when indicated
Important limitations
- This model is not calibrated to replace validated nomograms used in specialty clinics.
- It does not include prostate volume, MRI PI-RADS data, PSA density, or genomic markers.
- It cannot diagnose cancer and cannot determine treatment urgency by itself.
- Risk scores may perform differently across populations and healthcare settings.
Frequently asked questions
Is a high PSA always cancer?
No. Benign prostate enlargement, inflammation, infection, and recent instrumentation can raise PSA.
Can a normal DRE rule out cancer?
No. Some cancers are not palpable on exam, especially early or centrally located disease.
Should younger men use this tool?
Men under 40 are outside the intended scope here. Screening decisions at younger ages should be individualized by clinical history and risk profile.
Bottom line
This risk prostate cancer calculator is best used as a conversation starter. If your score is moderate or high, do not panic—but do follow up promptly. Early, informed evaluation is one of the best ways to detect clinically important disease while treatment options are strongest.